

Daniel Birnbaum

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1399258/daniel-birnbaum-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217
papers

19,077
citations

69
h-index

136
g-index

237
ext. papers

21,585
ext. citations

7.9
avg, IF

5.98
L-index

#	Paper	IF	Citations
217	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. <i>Cell Stem Cell</i> , 2007 , 1, 555-67	18	3079
216	Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. <i>Cancer Research</i> , 2009 , 69, 1302-13	10.1	938
215	Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. <i>Stem Cell Reports</i> , 2014 , 2, 78-91	8	656
214	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. <i>Journal of Clinical Investigation</i> , 2010 , 120, 485-97	15.9	577
213	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 45-55	12.9	570
212	Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009 , 145, 788-800	4.5	460
211	Gene expression profiling of breast cell lines identifies potential new basal markers. <i>Oncogene</i> , 2006 , 25, 2273-84	9.2	425
210	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3609-22	15.9	391
209	Prognostic score including gene mutations in chronic myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2428-36	2.2	373
208	How basal are triple-negative breast cancers?. <i>International Journal of Cancer</i> , 2008 , 123, 236-40	7.5	336
207	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015 , 6, 5449-64	3.3	313
206	Mutations of ASXL1 gene in myeloproliferative neoplasms. <i>Leukemia</i> , 2009 , 23, 2183-6	10.7	260
205	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019 , 569, 560-564	50.4	256
204	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. <i>Nature Chemistry</i> , 2017 , 9, 1025-1033	13.6	254
203	Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. <i>Cancer Research</i> , 2006 , 66, 4636-44	10.1	235
202	Integrated profiling of basal and luminal breast cancers. <i>Cancer Research</i> , 2007 , 67, 11565-75	10.1	232
201	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009 , 114, 3285-91	2.2	231

200	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. <i>Leukemia</i> , 2010 , 24, 1094-6	10.7	201
199	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009 , 94, 1676-81	6.6	198
198	A gene expression signature identifies two prognostic subgroups of basal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 407-20	4.4	192
197	A refined molecular taxonomy of breast cancer. <i>Oncogene</i> , 2012 , 31, 1196-206	9.2	190
196	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 3211-8	2.2	188
195	Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 12	22.4	187
194	Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. <i>Cancer Research</i> , 2005 , 65, 2170-8	10.1	186
193	Comprehensive profiling of 8p11-12 amplification in breast cancer. <i>Molecular Cancer Research</i> , 2005 , 3, 655-67	6.6	178
192	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 151, 365-75	4.5	175
191	The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1. <i>Blood</i> , 1999 , 93, 1381-1389	2.2	173
190	A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/hereregulin gene. <i>Cancer Research</i> , 2004 , 64, 6840-4	10.1	170
189	Retinoid signaling regulates breast cancer stem cell differentiation. <i>Cell Cycle</i> , 2009 , 8, 3297-302	4.7	168
188	Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. <i>Cancer Research</i> , 2004 , 64, 8558-65	10.1	155
187	Immunophenotypic analysis of inflammatory breast cancers: identification of an inflammatory signature. <i>Journal of Pathology</i> , 2004 , 202, 265-73	9.4	150
186	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013 , 122, 3169-77	2.2	147
185	FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. <i>Genes Chromosomes and Cancer</i> , 1993 , 7, 219-26	5	144
184	Cancer stem cells in breast: current opinion and future challenges. <i>Pathobiology</i> , 2008 , 75, 75-84	3.6	142
183	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. <i>Cancer Research</i> , 2005 , 65, 767-79	10.1	141

182	Basal breast cancer: a complex and deadly molecular subtype. <i>Current Molecular Medicine</i> , 2012 , 12, 96-119	5.9	139
181	MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 138-44	5	138
180	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. <i>PLoS Genetics</i> , 2012 , 8, e1002751	6	136
179	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. <i>American Journal of Pathology</i> , 2002 , 161, 1223-33	5.8	133
178	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. <i>BMC Cancer</i> , 2010 , 10, 401	4.8	125
177	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 743-55	5	119
176	Genome profiling of ERBB2-amplified breast cancers. <i>BMC Cancer</i> , 2010 , 10, 539	4.8	114
175	The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. <i>Clinical Cancer Research</i> , 2013 , 19, 6520-31	12.9	112
174	Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. <i>PLoS ONE</i> , 2011 , 6, e27656	3.7	108
173	Prognosis and gene expression profiling of 20q13-amplified breast cancers. <i>Clinical Cancer Research</i> , 2006 , 12, 4533-44	12.9	104
172	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. <i>BMC Cancer</i> , 2008 , 8, 299	4.8	102
171	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. <i>BMC Cancer</i> , 2007 , 7, 73	4.8	102
170	Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. <i>Oncogene</i> , 2006 , 25, 981-9	9.2	102
169	Myeloid malignancies: mutations, models and management. <i>BMC Cancer</i> , 2012 , 12, 304	4.8	101
168	Identification and validation of an ERBB2 gene expression signature in breast cancers. <i>Oncogene</i> , 2004 , 23, 2564-75	9.2	101
167	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. <i>Clinical Cancer Research</i> , 2013 , 19, 4685-96	12.9	99
166	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. <i>Cancer Research</i> , 2013 , 73, 7290-300	10.1	98
165	Genome profiling of pancreatic adenocarcinoma. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 456-65	5	98

164	Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. <i>Stem Cells</i> , 2012 , 30, 1327-37	5.8	97
163	Breast cancer stem cells: tools and models to rely on. <i>BMC Cancer</i> , 2009 , 9, 202	4.8	94
162	Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. <i>Oncogene</i> , 2008 , 27, 5359-72	9.2	94
161	Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. <i>Leukemia</i> , 2010 , 24, 469-73	10.7	93
160	Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. <i>Cancer Research</i> , 2011 , 71, 6621-32	10.1	91
159	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. <i>Leukemia</i> , 2013 , 27, 1401-3	10.7	88
158	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. <i>EMBO Molecular Medicine</i> , 2011 , 3, 153-66	12	88
157	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015 , 6, 13506-19	3.3	87
156	Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. <i>Cancer Research</i> , 2008 , 68, 767-76	10.1	86
155	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. <i>Cell Reports</i> , 2017 , 18, 2256-2268	10.6	81
154	TACC1-chTOG-Aurora A protein complex in breast cancer. <i>Oncogene</i> , 2003 , 22, 8102-16	9.2	81
153	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. <i>Nature Medicine</i> , 2017 , 23, 568-578	50.5	78
152	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. <i>Nature Communications</i> , 2016 , 7, 12222	17.4	77
151	The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. <i>Journal of Biological Chemistry</i> , 2001 , 276, 15256-63	5.4	74
150	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. <i>Oncogene</i> , 2007 , 26, 298-307	9.2	71
149	Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. <i>Journal of Immunology</i> , 2013 , 190, 2424-36	5.3	69
148	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. <i>Annals of Oncology</i> , 2014 , 25, 358-65	10.3	65
147	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. <i>Breast Cancer Research</i> , 2009 , 11, R23	8.3	65

146	Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 1420-33	7.6	62
145	Prognostic value of PDL1 expression in pancreatic cancer. <i>Oncotarget</i> , 2016 , 7, 71198-71210	3.3	59
144	Fifteen years of research on oral-facial-digital syndromes: from 1 to 16 causal genes. <i>Journal of Medical Genetics</i> , 2017 , 54, 371-380	5.8	58
143	Proteomics of breast cancer: principles and potential clinical applications. <i>Molecular and Cellular Proteomics</i> , 2006 , 5, 1772-86	7.6	58
142	Reasons for breast cancer heterogeneity. <i>Journal of Biology</i> , 2008 , 7, 6		57
141	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. <i>Oncogene</i> , 2002 , 21, 5619-30	9.2	56
140	Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. <i>Lancet Oncology, The</i> , 2001 , 2, 674-82	21.7	56
139	Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. <i>Nature Communications</i> , 2016 , 7, 10318	17.4	55
138	Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. <i>Leukemia</i> , 2008 , 22, 1567-75	10.7	53
137	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016 , 7, 27208-19	3.3	53
136	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015 , 6, 8388-96	3.3	52
135	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. <i>PLoS ONE</i> , 2011 , 6, e16950	3.7	50
134	Chromosome arm 8p and cancer: a fragile hypothesis. <i>Lancet Oncology, The</i> , 2003 , 4, 639-42	21.7	49
133	Mutations and deletions of ARID1A in breast tumors. <i>Oncogene</i> , 2012 , 31, 4255-6	9.2	47
132	Gene expression profiling and clinical outcome in breast cancer. <i>OMICS A Journal of Integrative Biology</i> , 2006 , 10, 429-43	3.8	47
131	Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. <i>Journal of Cell Science</i> , 2010 , 123, 2391-401	5.3	46
130	How different are luminal A and basal breast cancers?. <i>International Journal of Cancer</i> , 2009 , 124, 1338-48.5	4.5	46
129	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. <i>Genes Chromosomes and Cancer</i> , 2003 , 37, 333-45	5	46

128	Alteration of cohesin genes in myeloid diseases. <i>American Journal of Hematology</i> , 2010 , 85, 717-9	7.1	44
127	NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. <i>Leukemia</i> , 2008 , 22, 663-5	10.7	44
126	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. <i>PLoS ONE</i> , 2014 , 9, e81843	3.7	42
125	Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. <i>Leukemia</i> , 2009 , 23, 85-94	10.7	42
124	Gene expression profiling of inflammatory breast cancer. <i>Cancer</i> , 2010 , 116, 2783-93	6.4	42
123	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. <i>BMC Medicine</i> , 2017 , 15, 170	11.4	41
122	Aurora B -TACC1 protein complex in cytokinesis. <i>Oncogene</i> , 2004 , 23, 4516-22	9.2	41
121	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 495-508	4.4	40
120	Genomic profiling of inflammatory breast cancer: a review. <i>Breast</i> , 2014 , 23, 538-45	3.6	40
119	Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. <i>Oncogene</i> , 2011 , 30, 3862-74	9.2	40
118	Kinome expression profiling and prognosis of basal breast cancers. <i>Molecular Cancer</i> , 2011 , 10, 86	42.1	40
117	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. <i>Cancers</i> , 2019 , 11,	6.6	35
116	Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. <i>PLoS ONE</i> , 2014 , 9, e104302	3.7	35
115	The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 3585-601	7.6	35
114	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. <i>Haematologica</i> , 2014 , 99, 37-45	6.6	34
113	Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018 , 93, 330-338	7.1	34
112	Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2011 , 1, e33	7	33
111	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2017 , 28, 769-776	10.3	32

110	Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. <i>Journal of Translational Medicine</i> , 2015 , 13, 138	8.5	32
109	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 604-9	7.1	32
108	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. <i>Developmental Cell</i> , 2016 , 37, 311-325	10.2	32
107	ESPL1 is a candidate oncogene of luminal B breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 51-9	4.4	31
106	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31
105	OFIP/KIAA0753 Forms a complex with OFD1 and FOR20 at pericentriolar satellites and centrosomes and is mutated in one individual with oral-facial-digital syndrome. <i>Human Molecular Genetics</i> , 2016 , 25, 497-513	5.6	30
104	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. <i>Haematologica</i> , 2017 , 102, e11-e14	6.6	29
103	8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. <i>PLoS ONE</i> , 2012 , 7, e37943	3.7	27
102	Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. <i>Annals of Oncology</i> , 2013 , 24, 625-32	10.3	26
101	Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. <i>Leukemia</i> , 2016 , 30, 966-70	10.7	25
100	Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 176, 80-8		25
99	Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. <i>Stem Cells</i> , 2014 , 32, 3031-6	5.8	24
98	A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. <i>Molecular Cancer Research</i> , 2009 , 7, 402-14	6.6	24
97	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1383-1391	8.7	23
96	Signaling pathway switch in breast cancer. <i>Cancer Cell International</i> , 2013 , 13, 66	6.4	22
95	The centrosomal FOP protein is required for cell cycle progression and survival. <i>Cell Cycle</i> , 2009 , 8, 1217-27		22
94	A case of inv(8)(p11q24) associated with acute myeloid leukemia involves the MOZ and CBP genes in a masked t(8;16) 1999 , 26, 161-165		22
93	Validation and comparison of the molecular classifications of pancreatic carcinomas. <i>Molecular Cancer</i> , 2017 , 16, 168	42.1	21

92	MARCKS protein overexpression in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 6246-6257	3.3	21
91	Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2004 , 125, 601-4	4.5	19
90	Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 1996 , 15, 191-4	5	19
89	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2015 , 5, e292	7	18
88	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. <i>Breast Cancer Research</i> , 2011 , 13, R109	8.3	18
87	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. <i>Cancers</i> , 2019 , 11,	6.6	17
86	SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. <i>Nature Structural and Molecular Biology</i> , 2020 , 27, 438-449	17.6	16
85	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020 , 136, 698-714	2.2	16
84	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018 , 1869, 248-255	11.2	16
83	The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. <i>Annals of Oncology</i> , 2018 , 29, 459-465	10.3	16
82	EFA6B antagonizes breast cancer. <i>Cancer Research</i> , 2014 , 74, 5493-506	10.1	16
81	Alterations of NFIA in chronic malignant myeloid diseases. <i>Leukemia</i> , 2009 , 23, 583-5	10.7	16
80	Sensitive and easy screening for circulating tumor cells by flow cytometry. <i>JCI Insight</i> , 2019 , 5,	9.9	16
79	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , 2017 , 19, 564-573	6.4	15
78	Ajuba: a new microtubule-associated protein that interacts with BUBR1 and Aurora B at kinetochores in metaphase. <i>Biology of the Cell</i> , 2009 , 101, 221-35	3.5	15
77	PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019 , 13, 1577-1588	7.9	14
76	The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. <i>Npj Breast Cancer</i> , 2020 , 6, 8	7.8	14
75	Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2011 , 1, e18	7	14

74	Gene expression profiling of solitary fibrous tumors. <i>PLoS ONE</i> , 2013 , 8, e64497	3.7	13
73	Endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , 2011 , 364, 483-4; author reply 484-5	59.2	13
72	"Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. <i>Oncotarget</i> , 2012 , 1, 366-368	3.68	13
71	Genomic Grade Index predicts postoperative clinical outcome of GIST. <i>British Journal of Cancer</i> , 2012 , 107, 1433-41	8.7	13
70	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020 , 14, 504-519	7.9	13
69	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018 , 9, 33762-33777	3.3	13
68	A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. <i>International Journal of Molecular Medicine</i> , 2003 , 12, 423-8	4.4	13
67	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. <i>Cancers</i> , 2019 , 11,	6.6	12
66	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019 , 11, e9930	12	12
65	Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1035-47	4.4	12
64	The emerging role of the TGF β tumor suppressor pathway in pancreatic cancer. <i>Cell Cycle</i> , 2012 , 11, 683-64.7	11	11
63	Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. <i>Leukemia</i> , 2007 , 21, 2359-62	10.7	11
62	A reason why the ERBB2 gene is amplified and not mutated in breast cancer. <i>Cancer Cell International</i> , 2009 , 9, 5	6.4	10
61	Distant metastasis: not out of reach any more. <i>Journal of Biology</i> , 2009 , 8, 28		10
60	New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. <i>Haematologica</i> , 2007 , 92, 262-3	6.6	10
59	Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
58	Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia</i> , 2015 , 29, 500-2	10.7	9
57	SPAG5: the ultimate marker of proliferation in early breast cancer?. <i>Lancet Oncology, The</i> , 2016 , 17, 863-865	8.65	9

56	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. <i>Haematologica</i> , 2013 , 98, 576-83	6.6	9
55	The CINSARC signature: prognostic and predictive of response to chemotherapy?. <i>Cell Cycle</i> , 2010 , 9, 4025-7	4.7	9
54	Targeting breast cancer stem cells: fishing season open!. <i>Breast Cancer Research</i> , 2010 , 12, 312	8.3	9
53	De-repression of the RAC activator ELMO1 in cancer stem cells drives progression of TGFβ-deficient squamous cell carcinoma from transition zones. <i>ELife</i> , 2017 , 6,	8.9	9
52	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016 , 7, 79428-79441	3.3	8
51	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021 , 13, 87	14.4	8
50	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. <i>Pancreas</i> , 2017 , 46, e29-e31	2.6	7
49	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2019 , 120, 931-940	8.7	7
48	Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 363-73	4.4	7
47	Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines. <i>British Journal of Cancer</i> , 2005 , 92, 382-8	8.7	7
46	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. <i>Genes Chromosomes and Cancer</i> , 2019 , 59, 30	5	7
45	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. <i>Blood Cancer Journal</i> , 2020 , 10, 64	7	6
44	EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. <i>Blood</i> , 2020 , 135, 2004-2009	2.2	6
43	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. <i>Blood Cancer Journal</i> , 2017 , 7, e594	7	6
42	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. <i>Leukemia</i> , 2010 , 24, 1539-41	10.7	6
41	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. <i>In Vivo</i> , 2020 , 34, 177-184	2.3	6
40	Breast cancer stem cells programs: enter the (non)-code. <i>Briefings in Functional Genomics</i> , 2016 , 15, 186-199	4.9	5
39	Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	5

38	Mutation of FOP/FGFR1OP in mice recapitulates human short rib-polydactyly ciliopathy. <i>Human Molecular Genetics</i> , 2018 , 27, 3377-3391	5.6	5
37	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. <i>Cancers</i> , 2020 , 12,	6.6	5
36	"Wnt/ECatenin in GIST"-Letter. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 327-328	6.1	4
35	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019 , 11, 141	7.7	4
34	Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. <i>Cell Cycle</i> , 2012 , 11, 3141-24.7	4	
33	MARCKS protein overexpression is associated with poor prognosis in male breast cancer. <i>Cancer Biomarkers</i> , 2019 , 26, 513-522	3.8	4
32	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Onc Immunology</i> , 2021 , 10, 1929724	7.2	4
31	Gains of EPOR and ERG genes in adult erythroleukaemia. <i>British Journal of Haematology</i> , 2020 , 189, e174-177	4.5	3
30	How to best classify breast cancer: Conventional and novel classifications (Review) 2005 , 27, 1307		3
29	WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. <i>Advanced Science</i> , 2021 , 8, e2101030	13.6	3
28	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2314-2325	12.9	3
27	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Letter. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2324	6.1	2
26	Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. <i>PLoS ONE</i> , 2012 , 7, e43409	3.7	2
25	Breast cancer genomics: real-time use. <i>Lancet Oncology, The</i> , 2007 , 8, 1045-1047	21.7	2
24	Hypothesis: more mutations to cure cancer?. <i>Oncology Reports</i> , 1999 , 6, 1189-90	3.5	2
23	Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. <i>Haematologica</i> , 2020 , 105, e340-e342	6.6	2
22	A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1232186	1.2	2
21	Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1289-1293	1.9	2

20	Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020 , 24, 206-214	1.3	1
19	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019 , 11,	6.6	1
18	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. <i>Journal of Pathology</i> , 2012 , 227, 267-9	9.4	1
17	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. <i>Cell Death and Disease</i> , 2022 , 13, 96	9.8	1
16	EFA6B regulates a stop signal for collective invasion in breast cancer. <i>Nature Communications</i> , 2021 , 12, 2198	17.4	1
15	High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	1
14	Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade. <i>Annals of Oncology</i> , 2019 , 30, 342-343	10.3	1
13	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-8	3.6	1
12	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. <i>Npj Breast Cancer</i> , 2022 , 8, 12	7.8	0
11	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021 , 159, 205-214	7.5	0
10	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 48	7.8	0
9	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. <i>Journal of Personalized Medicine</i> , 2022 , 12, 655	3.6	0
8	ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. <i>Journal of Cellular Biochemistry</i> , 2020 , 121, 4870	4.7	
7	Flick the cancer stem cells switch to turn cancer off. <i>Molecular and Cellular Oncology</i> , 2017 , 4, e1319896 ^{1,2}		
6	Cellules souches du cancer du sein : prendre le cancer à la racine. <i>Oncologie</i> , 2012 , 14, 543-549	1	
5	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study 2012 , 225-242		
4	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. <i>Clinical Cancer Research</i> , 2020 , 26, 5539	12.9	
3	Epigenetically centered evolution in an example of myeloid malignancy. <i>American Journal of Hematology</i> , 2016 , 91, E361-2	7.1	

- 2 JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. *Hematological Oncology*, **2019**, 37, 201-201 1.3
- 1 Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of and Loss of .. *JCO Precision Oncology*, **2019**, 3, 1-9 3.6